Background
SOLID TUMORS, GASTRIC CANCER
Poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi) are approved for the treatment of various solid tumors. In gastric cancer, genes commonly harbor mutations in the homologous recombination DNA repair pathway, potentially increasing sensitivity to PARPi. Pamiparib (BGB‐290) is a small molecule inhibitor of PARP1 and PARP2.